Q-linea (QLINEA) Q3 2024 earnings summary

Executive summary

• Focused on rapid AST market of 5–7 million annual tests, targeting hospitals and labs in the US and Europe, with commercial acceleration and multiple evaluations completed or ongoing.

• US pipeline expanded, first contracts expected in Q4, and commercial team strengthened; instrument sales in Italy and ongoing discussions in UK and Belgium.

• Cost restructuring completed, reducing monthly operating costs to SEK 13.7–14 million, exceeding savings targets.

• Rights issue of SEK 225 million announced, secured to 80%, with bridge loan of SEK 40 million to fund operations for at least a year.

• ASTar received FDA approval and CMS NTAP reimbursement in the US, providing up to $97.50 per eligible patient.

Financial highlights

• Q3 operating result: SEK -41.2 million (improved from -48.3 million YoY), with average monthly operating result at SEK -13.7 million.

• Net sales for Q3: SEK 0.6 million, down from SEK 3.0 million YoY; nine-month sales: SEK 2.2 million.

• Cash and available loan facilities at quarter end: SEK 30.5 million, with SEK 7.5 million in cash and SEK 23 million in unused loan facility.

• Group equity at SEK 25.7 million; parent company equity at SEK 132.6 million, including SEK 70 million in Podler technology.

• Cost-saving program reduced annualized expenses by SEK 50 million.

Outlook and guidance

• Rights issue, bridge loan, and available cash expected to fund planned activities for the next 12 months.

• First US commercial placements expected in Q4 2024, with continued contract conversions in EMEA.

• Ongoing focus on expanding US and European commercial pipeline and converting evaluations to contracts.

• Continued product development, including Gram-positive menu and user experience improvements.

• Efforts to secure alternative financing, including strategic partnerships and further cost reductions.